Cargando…

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide

Tumor Treating Field (TTFields) therapy has demonstrated efficacy in a Phase 3 study of newly diagnosed glioblastoma (GB) following radiation (RT) and temozolomide (TMZ). We report the appearance of an isolated satellite anterior temporal lobe lesion, 2 months post primary RT/TMZ directed at the pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robins, H. Ian, Nguyen, HuyTram N., Field, Aaron, Howard, Steven, Salamat, Shahriar, Deming, Dustin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196276/ https://www.ncbi.nlm.nih.gov/pubmed/30374424 http://dx.doi.org/10.3389/fonc.2018.00451

Ejemplares similares

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide
por: Berger, Kerstin, et al.
Publicado: (2020)

Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity
por: Shi, Ping, et al.
Publicado: (2022)

Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields
por: Stein, Marco, et al.
Publicado: (2020)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine
por: Rubino, Sebastian, et al.
Publicado: (2018)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
por: Lo Dico, Alessia, et al.
Publicado: (2018)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma
por: Park, So Hee, et al.
Publicado: (2020)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
por: Bobola, Michael S., et al.
Publicado: (2012)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2020)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2021)

Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro
por: Matteoni, Silvia, et al.
Publicado: (2021)

Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype
por: Lombardi, Francesca, et al.
Publicado: (2022)

A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution
por: Song, Peng, et al.
Publicado: (2022)

Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
por: Vymazal, Josef, et al.
Publicado: (2023)

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
por: Wen, Patrick Yung, et al.
Publicado: (2020)

Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study
por: SAITO, Kuniaki, et al.
Publicado: (2014)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Enhancing glioblastoma treatment through the integration of tumor-treating fields
por: Szklener, Katarzyna, et al.
Publicado: (2023)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_crb1oss28lbma8o61qiuats4sc